Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393242 | 0.93 | ALDH1A1 (0.66) | ALDH1A1RAB9AHSD17B10EPHX1HTT | |
| SCHEMBL8396460 | 0.93 | ALDH1A1 (0.66) | ALDH1A1RAB9AHSD17B10EPHX1HTT | |
| SCHEMBL8395670 | 0.92 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1HTTNPC1 | |
| SCHEMBL8392988 | 0.92 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1HTTNPC1 | |
| SCHEMBL28551860 | 0.89 | ALDH1A1 (0.61) | ALDH1A1RAB9AHSD17B10HTT | |
| SCHEMBL25488384 | 0.87 | ALDH1A1 (0.63) | ALDH1A1RAB9AHSD17B10EPHX1HTT | |
| SCHEMBL9267844 | 0.87 | ALDH1A1 (0.61) | ALDH1A1RAB9AEPHX1HTTNPC1 | |
| SCHEMBL26576180 | 0.85 | ALDH1A1 (0.60) | ALDH1A1RAB9AHSD17B10HTTNPC1 | |
| SCHEMBL30407592 | 0.85 | ALDH1A1 (0.60) | ALDH1A1RAB9AHSD17B10HTTNPC1 | |
| SCHEMBL17658712 | 0.83 | NPC1 (0.56) | ALDH1A1RAB9ANPC1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4088/4885RAB9A 1848/4885HSD17B10 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.